伐尼克兰与安非他酮在慢阻肺吸烟者中的心血管及神经精神风险
基于QResearch数据库14 350例慢阻肺吸烟者的回顾性队列研究,比较伐尼克兰、安非他酮与尼古丁替代疗法(NRT)的心血管及神经精神不良事件风险。随访6个月发现,两种药物均未增加不良事件风险,伐尼克兰还与心力衰竭和抑郁风险降低相关。
要点
- 伐尼克兰与安非他酮未增加慢阻肺吸烟者心血管及神经精神事件风险。
- 伐尼克兰与心力衰竭风险降低(HR=0.56)和抑郁风险降低(HR=0.73)相关。
- 倾向性评分分析和未测量混杂建模支持上述结果稳健。
核心结论
- 在慢阻肺吸烟者中,与NRT相比,伐尼克兰和安非他酮不增加心血管事件、抑郁或自伤风险。
研究设计与样本
- 回顾性队列研究,使用QResearch数据库(覆盖英格兰753家NHS全科诊所)2007年1月至2012年6月数据,纳入14 350例慢阻肺患者。
- 暴露组:NRT组10 426例(参照)、安非他酮组350例、伐尼克兰组3 574例;随访6个月,采用Cox比例风险模型并调整混杂因素,辅以倾向性评分分析。
主要发现
- 与NRT相比,安非他酮和伐尼克兰均未显示不良事件风险增加。
- 伐尼克兰与心力衰竭风险显著降低相关(HR=0.56,95%CI 0.34-0.92)。
- 伐尼克兰与抑郁风险显著降低相关(HR=0.73,95%CI 0.61-0.86)。
- 倾向性评分分析获得相似结果,未测量混杂建模提示不良事件风险增加的可能性很低。
临床怎么用
- 对慢阻肺吸烟者处方伐尼克兰或安非他酮戒烟时,无需过度担忧心血管及神经精神不良事件风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Varenicline and bupropion are effective smoking cessation treatments, but there are concerns about their safety in smokers with COPD. OBJECTIVE: To investigate whether varenicline and bupropion are associated with serious adverse cardiovascular and neuropsychiatric events in smokers with COPD. METHODS: In a retrospective cohort study, we used data from 14 350 patients with COPD included in the QResearch database, which holds data from 753 National Health Service general practices across England. We identified patients with COPD who received a prescription of nicotine replacement therapy (NRT; N=10 426; reference group), bupropion (N=350) or varenicline (N=3574) in the period between January 2007 and June 2012. Patients were followed up for 6 months to compare incident cardiovascular (ie, ischaemic heart disease, stroke, heart failure, peripheral vascular disease and cardiac arrhythmias) and neuropsychiatric (ie, depression and self-harm) events using Cox proportional hazards models, adjusted for potential confounders. Propensity score analysis was used as an additional approach to account for potential confounding by indication. We also modelled the effects of possible unmeasured confounders. RESULTS: Neither bupropion nor varenicline showed an increased risk of adverse events compared with NRT. Varenicline was associated with a significantly reduced risk of heart failure (HR=0.56, 95% CI 0.34 to 0.92) and depression (HR=0.73, 95% CI 0.61 to 0.86). Similar results were obtained from the propensity score analysis. Modelling of unmeasured confounding provided additional evidence that an increased risk of these adverse events was very unlikely. CONCLUSION: In smokers with COPD, varenicline and bupropion do not appear to be associated with an increased risk of cardiovascular events, depression or self-harm in comparison with NRT.
引用
- Kotz D, Viechtbauer W, Simpson CR, et al. Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease. Thorax. 2017. PMID: 28473506. doi:10.1136/thoraxjnl-2017-210067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。